Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1273.529
- Development stage
- Phase 3
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1273.529 is an investigational, Omicron-specific (B.1.1.529) COVID-19 vaccine candidate developed by Moderna as a booster to enhance immunity against the SARS-CoV-2 Omicron variant. It is based on messenger RNA (mRNA) technology and encodes the spike protein of the Omicron BA.1 subvariant, aiming to induce neutralizing antibodies specifically targeting this variant. Preclinical studies in mice demonstrated that a primary vaccination series with mRNA-1273.529 potently neutralized B.1.1.529 but showed limited inhibition of historical or other SARS-CoV-2 variants; boosting with either mRNA-1273 or mRNA-1273.529 increased serum neutralizing titers and protection against B.1.1.529 infection. The vaccine has been evaluated in Phase 2/3 clinical trials as both a primary series and booster dose in adults previously vaccinated with earlier versions of Moderna's COVID vaccines.
- Other names
- COVID-19 vaccine Omicron variantCOVID19 vaccine Omicron variantCOVID 19 vaccine Omicron variant
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on mRNA-1273.529.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1273.529.